MyFinsight
Home
Blog
About
Contact
Download
Download image
Sale of ordinary
shares, pre-funded...
$8,248,261
Net cash provided by
financing activities
$6,763,040
Canceled cashflow
$1,485,221
Net change in cash
-$5,346,579
Canceled cashflow
$6,763,040
Impairment loss
$2,640,280
Stock option expense
(note 2)
$1,472,279
Share based
compensation
$1,202,954
Prepaid expenses and
other assets
-$791,288
Depreciation and
amortization
$615,720
Inventory write down
$312,151
Non-cash lease expense
$277,036
Accretion expense
$202,801
(gain) loss on sale and
disposal of assets
-$163,248
Accounts and other
receivable, net
-$114,630
Accounts payable and
accrued expense -...
$3,557
Proceeds from sales of
property and equipment
$17,815
Repayments of convertible
debt
$1,000,000
Payments on silent
partnerships
$243,405
Payments on loan payable
$241,816
Net cash used in
operating activities
-$10,979,587
Canceled cashflow
$7,795,944
Net cash used in
investing activities
-$1,033,401
Effect of changes in
exchange rates
-$96,631
Canceled cashflow
$17,815
Net loss
-$16,210,718
Accounts payable and
accrued liabilities...
-$2,073,730
Operating lease
liabilities
-$326,730
Inventories
$99,561
Accounts receivable -
related party
$43,792
Change in fair value of
convertible debt
$21,000
Payment for intangible
asset
$700,000
Payment for intangible
asset-related party
$350,000
Purchase of property and
equipment
$1,216
Back
Back
Cash Flow
source: myfinsight.com
MAINZ BIOMED N.V. (MYNZ)
MAINZ BIOMED N.V. (MYNZ)